Published on Web 12/02/2003
Synthetic Enantiopure Aziridinomitosenes: Preparation,
Reactivity, and DNA Alkylation Studies
Edwin Vedejs,*,† B. N. Naidu,† Artis Klapars,† Don L. Warner,† Ven-shun Li,‡
Younghwa Na,‡ and Harold Kohn*,‡,§
Contribution from the Departments of Chemistry, UniVersity of Michigan,
Ann Arbor, Michigan 48109, and UniVersity of Houston, Houston, Texas 77204
Received July 25, 2003; E-mail: edved@umich.edu
Abstract: An enantiocontrolled route to aziridinomitosenes had been developed from L-serine methyl ester
hydrochloride. The tetracyclic target ring system was assembled by an internal azomethine ylide cycloaddition
reaction based on silver ion-assisted intramolecular oxazole alkylation and cyanide-induced ylide generation
via a labile oxazoline intermediate (62 to 66). Other key steps include reductive detritylation of 26, methylation
of the N-H aziridine 56, oxidation of the sensitive cyclohexenedione 68 to quinone 70, and carbamoylation
using Fmoc-NCO. Although the aziridinomitosene tetracycle is sensitive, a range of protecting group
manipulations and redox chemistry can be performed if suitable precautions are taken. A study of DNA
alkylation by the first C-6,C-7-unsubstituted aziridinomitosene 11a has been carried out, and evidence for
DNA cross-link formation involving nucleophilic addition to the quinone subunit is described.
Mitomycins A (1), B (2), and C (3)1-3 have been the focus
of intensive study due to their fascinating structures, unusual
metabolic activation pathways, and clinical antitumor activity.4
Thus, 1, 3, and mitomycin K (4) have served as targets for total
synthesis,5-8 while 1 and 3 have been investigated in detail to
clarify the mechanisms of DNA alkylation (Scheme 1).1,9-12
Reductive activation of mitomycins generates leucoaziridi-
nomitosenes such as 5a, the intermediates responsible for DNA
cross-link formation.11 Leucoaziridinomitosenes are too reactive
for isolation, but 5a can be observed in solution using NMR
techniques,12 and the bis-silyl derivative 5b can be purified by
chromatography.13 Aziridinomitosenes 6, 7, 8, and 9 are
relatively stable, although they are more sensitive than the parent
mitomycins due to the activating effect of the indole nitrogen
on heterolysis of the aziridine C-N bond.1c,11,14,15 Aziridinomi-
tosenes do not require reductive activation to alkylate DNA, in
contrast to the mitomycins. Thus, 7 has been shown to
monoalkylate DNA,15 while 9 has in vivo activity similar to
that of mitomycin C.16
Several total syntheses of racemic mitomycins have been
reported,5-8 but there has been no enantioselective synthesis.17,18
Only one synthesis of a fully functional aziridinomitosene
(racemic 6) has been reported to date (Jimenez and Dong).19
The highly sensitive aziridine ring was installed in the final step,
a strategy that minimizes problems with reactivity but that
somewhat limits options for enantioselective synthesis.
Efforts in our laboratory have been focused on previously
unknown aziridinomitosenes such as 10, 11a, and 11b. These
structures contain potentially electrophilic sites at C-6 or C-7
† University of Michigan.
‡ University of Houston.
§ Current address: Division of Medicinal Chemistry and Natural Products,
School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599.
(1) Reviews: (a) Wolkenberg, S. E.; Boger, D. L. Chem. ReV. 2002, 102, 2477.
(b) Rajski, S. R.; Williams, R. M. Chem. ReV. 1998, 98, 2723. (c) Tomasz,
M.; Palom, Y. Pharmacol. Ther. 1997, 76, 73. (d) Danishefsky, S. J.;
Schkeryantz, J. M. Synlett 1995, 475. (e) Tomasz, M. Chem. Biol. 1995,
2, 575. (f) Kasai, M.; Kono, M. Synlett 1992, 778. (g) Franck, R. W.;
Tomasz, M. In The Chemistry of Antitumor Agents; Wilman, D. E. V.,
Ed.; Blackie and Sons: Scotland, 1989. (h) Remers, W. A. In The Chemistry
of Antitumor Antibiotics, Vol. 1; John Wiley & Sons: New York, 1979.
(2) (a) Hata, T.; Sano, Y.; Sugawara, R.; Matsumae, A.; Kanamori, K.; Shima,
T.; Hoshi, T. J. Antibiot. 1956, 9, 141. (b) Wakaki, S.; Marumo, H.;
Tomioka, K.; Shimizu, G.; Kato, E.; Kamada, H.; Kudo, S.; Fujimoto, Y.
Antibiot. Chemother. 1958, 8, 228.
(3) (a) Webb, J. S.; Cosulich, D. B.; Mowat, J. H.; Patrick, J. B.; Broschard,
R. W.; Meyer, W. E.; Williams, R. P.; Wolf, C. F.; Fulmor, W.; Pidacks,
C. J. Am. Chem. Soc. 1962, 84, 3187. (b) Tulinsky, A. J. Am. Chem. Soc.
1962, 84, 3190. (c) Shirahata, K.; Hirayama, N. J. Am. Chem. Soc. 1983,
105, 7199.
(13) Egbertson, M.; Danishefsky, S. J. J. Am. Chem. Soc. 1987, 109, 2204.
(14) Patrick, J. B.; Williams, R. P.; Meyer, W. E.; Fulmor, W.; Cosulich, D.
B.; Broschard, R. W.; Webb, J. S. J. Am. Chem. Soc. 1964, 86, 1889.
(15) (a) Han, I.; Kohn, H. J. Org. Chem. 1991, 56, 4648. (b) Li, V.-S.; Choi,
D.; Tang, M.-S.; Kohn, H. J. Am. Chem. Soc. 1996, 118, 3765.
(16) Iyengar, B. S.; Remers, W. A.; Bradner, W. T. J. Med. Chem. 1986, 29,
1864.
(17) (a) Papaioannou, N.; Evans, C. A.; Blank, J. T.; Miller, S. J. Org. Lett.
2001, 3, 2879. (b) Ziegler, F. E.; Berlin, M. Y. Tetrahedron Lett. 1998,
39, 2455.
(4) Iyer, V. N.; Szybalski, W. Science 1964, 145, 55.
(5) (a) Nakatsubo, F.; Fukuyama, T.; Cocuzza, A. J.; Kishi, Y. J. Am. Chem.
Soc. 1977, 99, 8115. (b) Fukuyama, T.; Nakatsubo, F.; Cocuzza, A. J.;
Kishi, Y. Tetrahedron Lett. 1977, 4295. (c) Kishi, Y. J. Nat. Prod. 1979,
42, 549.
(6) (a) Fukuyama, T.; Yang, L. J. Am. Chem. Soc. 1989, 111, 8303. (b)
Fukuyama, T.; Yang, L. J. Am. Chem. Soc. 1987, 109, 7881.
(7) Benbow, J. W.; McClure, K. F.; Danishefsky, S. J. J. Am. Chem. Soc. 1993,
115, 12305.
(8) Wang, Z.; Jimenez, L. S. Tetrahedron Lett. 1996, 37, 6049.
(9) Iyer, V. N.; Szybalski, W. Proc. Natl. Acad. Sci. U.S.A. 1963, 50, 335.
(10) Tomasz, M.; Lipman, R.; Chowdary, D.; Pawlek, J.; Verdine, G. L.;
Nakanishi, K. Science 1987, 235, 1204.
(18) For enantioselective approaches, see: (a) Vedejs, E.; Little, J. J. Am. Chem.
Soc. 2002, 124, 748. (b) Michael, J. P.; de Koning, C. B.; Petersen, R. L.;
Stanbury, T. V. Tetrahedron Lett. 2001 42, 7513. (c) Lee, S.; Lee, W.-M.;
Sulikowski, G. A. J. Org. Chem. 1999, 64, 4224. (d) Utsunomiya, I.; Fuji,
M.; Sato, T.; Natsume, M. Chem. Pharm. Bull. 1993, 41, 854. (e) Shaw,
K. J.; Luly, J. R.; Rapoport, H. J. Org. Chem. 1985, 50, 4515.
(19) Dong, W.; Jimenez, L. S. J. Org. Chem. 1999, 64, 2520.
(11) Cummings, J.; Spanswick, V. J.; Tomasz, M.; Smyth, J. F. Biochem.
Pharmacol. 1998, 56, 405.
(12) Danishefsky, S. J.; Egbertson, M. J. Am. Chem. Soc. 1986, 108, 4648.
9
15796
J. AM. CHEM. SOC. 2003, 125, 15796-15806
10.1021/ja030452m CCC: $25.00 © 2003 American Chemical Society